PCML
ALT icon

Pavaki Capital Management LLC’s Altimmune ALT Stock Holding History

Pavaki Capital Management LLC’s Portfolio ALT Stock Details ALT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-215,400
Closed -$778K – 157
2025
Q4 		$778K Buy
+215,400
New +$939K 0.3% 52

Other funds holding ALT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Pavaki Capital Management LLC's ALT Position: Q1 2026 in Review

Pavaki Capital Management LLC sold out of Altimmune (ALT) in Q1 2026, closing a stake of 215,400 shares — an estimated $778K sold.

Pavaki Capital Management LLC first reported a position in ALT in Q4 2025 and held it in 1 quarter. The position peaked at $778K in Q4 2025. 173 funds tracked by Wall St. Rank hold ALT as of Q1 2026.

  • Pavaki Capital Management LLC reported no remaining Altimmune position as of Q1 2026 after selling out during the quarter.
  • Pavaki Capital Management LLC sold 215,400 Altimmune shares in Q1 2026, an estimated $778K.
  • Pavaki Capital Management LLC first reported a position in Altimmune in Q4 2025 and held it in 1 quarter.
  • Pavaki Capital Management LLC's Altimmune position peaked at $778K in Q4 2025.
  • 173 funds tracked by Wall St. Rank held Altimmune as of Q1 2026.

Based on Pavaki Capital Management LLC's 13F filing for Q1 2026, filed 7 Aug 2026.